Loading
TGRX-326 is an experimental small-molecule drug from Shenzhen TargetRx in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
TGRX-326 is a small-molecule drug developed by Shenzhen TargetRx. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: Subjects will be treated with the investigational drug TGRX-326 at 60 mg once day in 21-day cycles. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06082635 (TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)), in non-small-cell lung cancer. The largest, NCT06082635, plans to enrol 321 participants (actual) with primary completion was scheduled for 2026-04-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.TGRX-326 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TGRX-326" OR ABSTRACT:"TGRX-326" OR TITLE:"TGRX-326 QD once a day" OR ABSTRACT:"TGRX-326 QD once a day") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TGRX-326, not a curated reading list.
Shares Shenzhen TargetRx and the tag pipeline.
Shares Shenzhen TargetRx and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.